Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. The company’s strategy is to develop products and form marketing collaborations with industry leaders to maximize the products’ commercial potential. PTN has licensed several families of melanocortin receptor-based compounds for treatment of obesity, diabetes and related metabolic syndrome to AstraZeneca. For more information, visit the company’s Web site: http://www.palatin.com
Let us hear your thoughts below: